Galectin Therapeutics Inc. (GALT) stock slips after being downgraded at FBR & Co

Galectin Therapeutics Inc. (NASDAQ: GALT) shares fell in early trading today on lower trade volume than normal after a number of analysts weighed in on the investing value of the stock with a downgraded rating.

Analysts at FBR & Co downgraded shares of Galectin Therapeutics Inc. (NASDAQ: GALT) from Outperform to Market Perform in a research note to investors today. With a rating of Market Perform on the stock, Galectin Therapeutics Inc. has a 52-week high of $3.25. The one-year price target of $1.13 is above the opening price of $1.12, causing a fair amount of other analysts to comment on the stock recently. Downgrades are more likely when analysts feel that the future prospects for the security have dropped from the original recommendation, often because of an important and major digression in the company’s operations, future vision or industry.

Meanwhile, US stock opened lower amid concerns surrounding the U.S. Department of Justice’s probe into Deutsche Bank AG.

The S&P 500 SPX, -0.25% slipped 5 points, or 0.2%, to 2,162.

The Dow industrials DJIA, -0.26% fell 55 points, or 0.3%, to 18,252.

The Nasdaq Composite COMP, -0.11% was off 13 points, or 0.3%, to 5,298

Shares of Galectin Therapeutics Inc. (NASDAQ: GALT) opened at $1.12 yesterday trading between $1.08 and $1.13, and last traded at $1.08, which is a dip of $0.04 per share or -0.04 over the previous closing price.

Galectin Therapeutics Inc. (NASDAQ: GALT) currently has a market cap of 31.77M.

Galectin Therapeutics Inc.Trading Volume

275,641 shares traded hands yesterday, lower than normal, out of a total float 22,679,000. Look for trading volume to pick up in the coming days as swing traders often use swings in trading volume to pinpoint heavy volume accumulation or distribution by institutional investors.

While an increase in trading for short periods will not mean much, conversely, a trend of heavy trading volume on the buy side over a series of days or weeks sends a positive signal to market traders that institutions may be moving in, so institutional sponsorship is crucial.

Institutional sponsorship is defined by ownership of a stock by mutual funds, banks, pension funds and other large institutions.

These instituitional investors retain teams of analysts that research thousands of stocks. Thus, watching their interests is a good way to ensure you are buying the right stocks.

Galectin Therapeutics Inc. Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

By marking the activity of these professional investors and how they influence moving averages, traders can make educated trades.

With that in mind, Galectin Therapeutics Inc. (NASDAQ: GALT) now has a 50-day MA of $1.86 and 200-day MA of $1.60. It has traded in a 52-week range between $1.08 – 3.250 and today’s last price is 0.67% lower than the 52 week high of $3.25.

Indeed, earnings growth is among the most crucial things to look at in regards to stock investing and, accordingly, investors watch for companies that have increased their earnings at least 25% or more over the past 3 years.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *